Metropolis Healthcare Limited (“Metropolis”) is one of the leading diagnostic companies in India in terms of revenue with a presence across 19 states. Metropolis offers a broad range tests and has implemented a “Hub & Spoke” model for swift delivery of services through their vast delivery network. Through this model they operate in 197 cities in India as of
Dec’ 18
Valuation and Outlook
At the upper end of the price band, Metropolis is valued at a P/E of ~38x on TTM basis which is largely in line with the average of the other two listed players in the diagnostics space. We believe the company is well‐poised to deliver strong earnings growth in the forthcoming years considering the fragmented & under penetrated diagnostic market. We recommend investors to SUBSCRIBE the issue and hold the stock with a long term perspective.
For all IPO stories, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!